All In Biotech

Drug Trial Radar · NCT06693843

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

230

Actual

Start

Oct 28, 2024

Primary completion

Oct 24, 2025

Study completion Jul 9, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.

Conditions

  • Obesity, Overweight, or Chronic Weight Management

Interventions

  • Aleniglipron or PlaceboDrug

    Drug: Aleniglipron Administered orally Drug: Placebo Administered orally

  • Aleniglipron or PlaceboDrug

    Drug: Aleniglipron Administered orally Drug: Placebo Administered orally

  • Aleniglipron or PlaceboDrug

    Drug: Aleniglipron Administered orally Drug: Placebo Administered orally

  • AleniglipronDrug

    Drug: Aleniglipron Administered orally

  • AleniglipronDrug

    Drug: Aleniglipron Administered orally

  • AleniglipronDrug

    Drug: Aleniglipron Administered orally

  • AleniglipronDrug

    Drug: Aleniglipron Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from Baseline to Week 36Time frame: Baseline and week 36
  2. TEAEs and SAEsTime frame: Baseline and week 72
  3. AESITime frame: Baseline and week 72
  4. Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulationTime frame: Baseline and week 72
  5. Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF)Time frame: Baseline and week 72
  6. Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperatureTime frame: Baseline and week 72

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • ACCESS Research Site

    Phoenix, Arizona

  • ACCESS Research Site

    Anaheim, California

  • ACCESS Research Site

    Los Angeles, California

  • ACCESS Research Site

    Montclair, California

  • ACCESS Research Site

    Rancho Cucamonga, California

  • ACCESS Research Site

    Sacramento, California

  • ACCESS Research Site

    Spring Valley, California

  • ACCESS Research Site

    Honolulu, Hawaii

  • ACCESS Research Site

    Chicago, Illinois

  • ACCESS Research Site

    Chicago, Illinois

  • ACCESS Research Site

    Evanston, Illinois

  • ACCESS Research Site

    Muncie, Indiana

  • ACCESS Research Site

    Valparaiso, Indiana

  • ACCESS Research Site

    West Des Moines, Iowa

  • ACCESS Research Site

    Baton Rouge, Louisiana

  • ACCESS Research Site

    Richfield, Minnesota

  • ACCESS Research Site

    City of Saint Peters, Missouri

  • ACCESS Research Site

    Hazelwood, Missouri

  • ACCESS Research Site

    Springfield, Missouri

  • ACCESS Research Site

    Albany, New York

  • ACCESS Research Site

    Binghamton, New York

  • ACCESS Research Site

    Brooklyn, New York

  • ACCESS Research Site

    Rochester, New York

  • ACCESS Research Site

    Wilmington, North Carolina

  • ACCESS Research Site

    Cincinnati, Ohio

  • ACCESS Research Site

    Norman, Oklahoma

  • ACCESS Research Site

    Medford, Oregon

  • ACCESS Research Site

    Pittsburgh, Pennsylvania

  • ACCESS Research Site

    Moncks Corner, South Carolina

  • ACCESS Research Site

    Chattanooga, Tennessee

  • ACCESS Research Site

    Austin, Texas

  • ACCESS Research Site

    Austin, Texas

  • ACCESS Research Site

    Dallas, Texas

  • ACCESS Research Site

    Dallas, Texas

  • ACCESS Research Site

    Mesquite, Texas

  • ACCESS Research Site

    Shavano Park, Texas

  • ACCESS Research Site

    West Jordan, Utah

  • ACCESS Research Site

    Winchester, Virginia

  • ACCESS Research Site

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.